Thymos Health · For Referring Providers
A partner for the patients you can't quite close the loop on.
Thymos Health exists for the patients with multi-system symptoms that need expedited diagnoses and continuous care customized to their unique data.
We'll handle the multi-specialty longitudinal autoimmune care and report back regularly.
34.4%
Of autoimmune patients have 2 or more autoimmune diseases1
2.5–7.5yrs
Average diagnosis delay with 75% misdiagnosed2
65%
Of autoimmune patients never achieve meaningful relief on standard therapy3
The Problem You Already Know
Getting a diagnosis doesn't mean getting better.
Your patients with various symptoms that aren't explained by one diagnosis are common. The research bears out what you already know: autoimmune diseases are a multi-system, multi-specialist, multi-year problem.
Why Autoimmune Disease Is So Complex
60% of autoimmune diseases need input from 2+ providers before an accurate diagnosis is reached.4
Symptoms and treatment response with autoimmune diseases often evolve between visits.
The majority of patients on immunotherapy never achieve meaningful relief.6
Most patients need multi-system medical management and continuous monitoring to prevent disease progression within a few years.
The Thymos Model
From referral to ongoing co-management.
We help you do more for your patients and providers.
Thymos collaborates with prescribing clinicians, pairing patients with our board-certified autoimmune specialists, continuous monitoring, and 24/7 support. We are an extension of your medical team, enhancing patient outcomes.
1
Refer patients whose symptoms don't fit into one diagnosis – or those poorly responsive to standard treatment
2
Thymos physicians co-manage autoimmune-specific care, 24/7 support, remote monitoring, and care coordination
How our model works
Our validated clinical analysis model uses thousands of deterministic algorithms and hybrid AI to turn fragmented records, comprehensive medical history, and diagnostic results into one whole-person view. Active, data-guided intervention between visits flags disease patterns early and fine-tunes treatment in real-time.6 See how it works with real patient cases.
3
Maintain continuous visibility of your patients
Thymos continuously shares findings with you to help you better support your patients towards optimal health.
What Co-Management Means For You
Co-Management with Expertise, Coordination, and Support.
Gain a co-manager for your hardest autoimmune cases.
01 · Expertise
One team, every specialty your patients need
Thymos manages complex cases across the whole system and tailors treatments to the root causes, symptoms, and diagnoses.
02 · Coordination
One coordinated, whole-person view
Thymos provides monthly consults and prioritizes cross-specialist coordination, keeping every physician in the loop.
03 · 24/7 Support
Longitudinal medical management
24/7 clinical support and remote monitoring flag disease patterns early and fine-tune treatment in real time.
Referring to Thymos means gaining a co-manager on your hardest cases.
Value-Based Care Enablement
Helping providers stay ahead of the value-based care curve.
Thymos Health helps providers succeed in autoimmune-focused value-based care arrangements. We act as an extension of your providers by offering dedicated care support, technology, and expertise.
01 · Results
Enhance patient care and outcomes
Our physicians offer high-frequency whole-system expertise, remote monitoring, and 24/7 clinical support, proactively managing patients' symptoms and flagging disease patterns early.
02 · Efficiency
Unlock clinical and staff efficiency
Thymos is an extension of your care team, reducing your workload and ensuring your patients feel fully supported.
03 · Revenue
Pursue value-based care in confidence
Our autoimmune-focused Performance Programs enable providers to succeed in value-based care arrangements and generate additional revenue without taking downside risk.
Ready to co-manage your next complex case with us?
Refer a complex case, or send us a patient who's been on a biologic a little too long without anyone revisiting why.
HIPAA-compliant intake · No EHR integration required to start · You remain the doctor of record
Sources & Citations
▼
[1]
Rojas-Villarraga A, Amaya-Amaya J, Rodriguez-Rodriguez A, Mantilla RD, Anaya JM. Introducing Polyautoimmunity: Secondary Autoimmune Diseases No Longer Exist. Autoimmune Diseases, 2012. Of 1,083 patients with autoimmune disease, 373 (34.4%) had polyautoimmunity; autoimmune thyroid disease and Sjögren's syndrome were the most frequently encountered additional diseases.
PMC: PMC3290803
[2]
Diagnostic Delay in Psoriatic Arthritis: A Population-based Study. The Journal of Rheumatology, 2021; and Increased Musculoskeletal Surgery Rates During Diagnostic Delay in Psoriatic Arthritis. Retrospective cohort. Median delay 2.5 years in a population-based cohort; mean delay 7.49 years in a separate real-world cohort, with 27.4% undergoing at least one musculoskeletal surgery during the delay period.
Source: jrheum.org · PMC: PMC12071673
[3]
Thymos Health internal employer-facing materials (employer landing page, employer pitch deck), 2026. Cited there as an illustrative figure describing the share of autoimmune patients who report no meaningful relief while remaining on standard therapy. This is an internal Thymos figure used consistently across our employer-facing materials, not a peer-reviewed or externally published finding.
Source: Thymos Health internal program materials — not externally published
[4]
Addison's Disease: The Critical Role of Timely Diagnosis. ScienceDirect, 2026. Approximately 60% of diagnosed Addison's disease cases required input from 2 or more providers before arriving at the correct diagnosis.
Source: sciencedirect.com
[5]
Taylor PC, Matucci Cerinic M, Alten R, Avouac J, Westhovens R. Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes. Therapeutic Advances in Musculoskeletal Disease, 2022. Up to 40% of patients respond inadequately to an initial anti-TNF (biologic) treatment due to primary non-response, secondary loss of response, or intolerance — consistent with multiple independent studies reporting a 20–40%+ inadequate-response range across biologic classes.
Source: journals.sagepub.com · PMC: PMC9386864
[6]
Thymos Health internal employer program materials (employer pitch deck, employer landing page, and ROI/payback model), 2026. Approximately 8% of a typical covered workforce has an autoimmune condition; most patients who reach biologic therapy remain on it indefinitely by default. Program modeling (a flat $500/participant/month fee vs. an average $5,000/month biologic AWP) estimates that engaging and successfully tapering just 1 in 10 high-cost patients is sufficient to generate a positive return over the full 24-month program. These are internal financial projections, not findings from a peer-reviewed clinical outcomes study.
Source: Thymos Health internal program materials — not externally published